Skip to content

20-068 - Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)

Status: open

A Multicenter, Longitudinal, Open-label, Single-arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod

Patients with Relapsing Multiple Sclerosis

Contact Us Or call +1 (251) 665-8375

Description

This is a phase 3 clinical trial with ozanimod in relapsing forms of multiple sclerosis. The primary objective is to determine if and how cognition changes when taking ozanimod. This is a 3 year study with approximately 4 visits per year.

Sponsors

This trial is sponsored by Celgene.

Providers Associated With This Trial

Sub Investigators

This link will open in a new tab or window.